Form 4: United Therapeutics EVP Paul Mahon Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on March 21, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 21, 2024, Paul A. Mahon, the EVP & General Counsel of United Therapeutics Corp (UTHR), exercised stock options to acquire 6,000 shares of common stock at a price of $117.76 per share.
- Simultaneously, Mahon sold a total of 6,000 shares in multiple transactions at weighted average prices ranging from $234.1121 to $237.3601.
- These transactions were executed under a pre-existing Rule 10b5-1 trading plan.
- Following these transactions, Mahon directly owns 36,710 shares of United Therapeutics common stock.
- Mahon also owns 54,000 derivative securities in the form of stock options.
Sentiment
Score: 5
Explanation: Neutral sentiment as it reflects routine insider trading activity under a pre-arranged plan.
Positives
- The transactions were executed under a pre-existing Rule 10b5-1 trading plan, which suggests that the sales were planned and not based on any inside information.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid any appearance of trading on inside information. The market will likely interpret this as a standard executive compensation activity.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- Rule 10b5-1 trading plans are a common practice among corporate executives to manage their stock holdings and avoid insider trading accusations.
- Comparable companies like Gilead Sciences, Amgen, and Biogen also see regular Form 4 filings from their executives related to stock option exercises and sales.
Stakeholder Impact
- The transactions are unlikely to have a significant impact on shareholders, employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Date stock options were exercisable |
| 03/21/2024 | Date of stock option exercise and share sales |
| 03/22/2024 | Date of signature on the SEC Form 4 |
| 03/15/2027 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.